Naz Rahman
Stock Analyst at Maxim Group
(0.36)
# 4,019
Out of 4,732 analysts
37
Total ratings
17.86%
Success rate
-40.92%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.09 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $4.76 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $1.48 | +440.54% | 7 | Nov 13, 2024 | |
| SLXN Silexion Therapeutics | Initiates: Buy | $9 | $0.88 | +922.73% | 1 | Nov 1, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $3.02 | - | 2 | Oct 24, 2024 | |
| VRPX Virpax Pharmaceuticals | Downgrades: Hold | n/a | $0.30 | - | 4 | Oct 9, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $3 | $0.83 | +262.63% | 1 | Jul 26, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $120 | $32.65 | +267.53% | 4 | Jun 4, 2024 | |
| QNRX Quoin Pharmaceuticals | Maintains: Buy | $15 → $4 | $0.57 | +600.28% | 2 | Mar 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Hold | n/a | $422.00 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.30 | +1,232.89% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.81 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.72 | +191.55% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $20 | $3.28 | +509.76% | 2 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.56 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $3.50 | +71.43% | 1 | Feb 25, 2022 |
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.09
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $4.76
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.48
Upside: +440.54%
Silexion Therapeutics
Nov 1, 2024
Initiates: Buy
Price Target: $9
Current: $0.88
Upside: +922.73%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.02
Upside: -
Virpax Pharmaceuticals
Oct 9, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.30
Upside: -
Assertio Holdings
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.83
Upside: +262.63%
Viking Therapeutics
Jun 4, 2024
Reiterates: Buy
Price Target: $120
Current: $32.65
Upside: +267.53%
Quoin Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $15 → $4
Current: $0.57
Upside: +600.28%
Vertex Pharmaceuticals
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $422.00
Upside: -
Dec 8, 2023
Initiates: Buy
Price Target: $4
Current: $0.30
Upside: +1,232.89%
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.81
Upside: -
Aug 9, 2023
Initiates: Buy
Price Target: $5
Current: $1.72
Upside: +191.55%
May 11, 2023
Maintains: Buy
Price Target: $13 → $20
Current: $3.28
Upside: +509.76%
May 9, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.56
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $3.50
Upside: +71.43%